Across TCGA pan-cancer cohorts, ARID3C RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated ARID3C data layer compared with 4 for mutation status.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ARID3C RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARID3C expression acts as an unfavorable survival marker, although some lineages such as ESCA and HNSC show a favorable association.
KIRC, KIRP, and BLCA are the cancer types where ARID3C RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.